Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Filings indexed 1,091 across all filing types
Latest filing 2026-05-15 Regulatory Filings
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-15 English
10-Q
Interim / Quarterly Report
2026-05-15 English
S-3 - GALECTIN THERAPEUTICS INC (0001133416) (Filer)
Regulatory Filings
2026-03-31 English
8-K - GALECTIN THERAPEUTICS INC (0001133416) (Filer)
Regulatory Filings
2026-03-31 English
10-K - GALECTIN THERAPEUTICS INC (0001133416) (Filer)
Annual Report FY 2025
2026-03-31 English
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
Director's Dealing
2026-03-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.